About Kyle Dempsey
Kyle Dempsey is a director at GT Medical Technologies.
Kyle Dempsey reports to the SEC as a director of 1 public company: OptiNose (OPTN).
Kyle Dempsey first appears on SEC filings in 2020.
Experience
This experience comes from Kyle Dempsey's profile and from SEC filings. For roles taken from filings, the years are when the filings name Kyle Dempsey in the role, so the role may have started earlier or lasted longer.
NM
Neurent Medical Current
Board Director
2026 – Present
GT Medical Technologies, Inc. Current
Director
2020 – Present · Tempe, AZ
Makes radiation implants for patients undergoing brain tumor surgery.
ML
MVM Partners LLP Current
Partner
2017 – Present
HI
HLS Therapeutics Inc.
Board Director
2022 – 2026
OI
OptiNose, Inc.
Director
2021 – 2025 · Public company (OPTN)
BI
Biotheranostics, Inc.
Board Observer
2018 – 2021
BC
Bain & Company
Consultant
2015 – 2017
AA
American Medical Association
Co-Chair
2012 – 2014
MH
Massachusetts General Hospital
Clinic Director, Research Team Co-Director, and Board Member
2011 – 2014
Key Colleagues at Startups
The people Kyle Dempsey works with at each company, as listed on that company's latest Form D.
GT Medical Technologies, Inc. · Form D, Jul 22, 2026
SA
Susana Amorim
Director
JR
Jason Rostovsky
Director
PL
Prattipati Laxminarain
Executive officer and director
James Leech
Chief Financial and Strategy Officer
Per Langoe
Chief Executive Officer and director
PE
Paul Enever
Director
David Brachman
Co-Founder and Chief Technology Officer, director